Zynteglo Is Cost Effective At $2.1M, ICER Proposes; Validation For Bluebird’s Pivot To US?

Draft evidence report from the Institute for Clinical and Economic Review on the potentially curative rare disease treatment also supports the narrative that the unrestricted pricing environment in the US invites greater access to innovative treatments compared to markets abroad. 

ICER Analysis Is Based On A Price Estimate For Zynteglo In US • Source: Alamy

bluebird bio’s gene therapy for beta thalassemia, Zynteglo (betibeglogene autotemcel), would be cost effective at a price of $2.1m, especially if payments are spread over five years and based on outcomes, the Institute for Clinical and Economic Review tentatively concludes in a draft evidence report released 13 April.

“Despite remaining uncertainties, the evidence suggests that beti-cel provides net health benefits to patient with [transfusion dependent thalassemia] and given the high annual costs of standard of care, traditional cost effectiveness modeling finds that this new treatment meets commonly accepted value thresholds at a cumulative price of $2

More from Health Technology Assessment

More from Market Access